@adamispharmaceuticals.com
DMK Pharmaceuticals is developing high quality, lower-cost respiratory and allergy therapies for a changing healthcare landscape.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company that is dedicated to addressing the changing healthcare landscape by developing high-quality, lower-cost respiratory and allergy therapies. With a focus on putting patients first, Adamis Pharmaceuticals is committed to providing solutions for a variety of neuro-based disorders with significant unmet medical needs. Their commercially approved products include ZIMHI® (naloxone) Injection, which is FDA approved for opioid overdose emergency rescue, and SYMJEPI® (epinephrine) Injection, which is FDA approved for the emergency treatment of acute allergic reactions, including anaphylaxis.
In addition to their current products, Adamis Pharmaceuticals has a robust pipeline of molecules in development. This includes DPI-125 for the treatment of Opioid Use Disorder (OUD), DPI-221 for the treatment of benign prostatic hyperplasia (BPH), and DPI-289 for the treatment of Parkinson's disease. Committed to their mission, Adamis Pharmaceuticals is a trusted brand that is dedicated to providing innovative solutions for patients in need
Company Size
11-50
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online